Literature DB >> 25576170

Monthly microperimetry (MP1) measurement of macular sensitivity after dexamethasone implantation (Ozurdex) in retinal vein occlusions.

Sibylle Winterhalter1, Gerrit Alexander Vom Brocke2, Matthias K Klamann2, Bert Müller2, Antonia M Joussen2.   

Abstract

PURPOSE: To evaluate changes in macular sensitivity as measured via microperimetry (MP) in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) after dexamethasone implantation (DEX implantation, Ozurdex), in comparison to distance visual acuity, reading ability, and spectral domain optical coherence tomography (SD-OCT).
METHODS: Twenty-three patients with ME secondary to RVO were treated with a DEX implantation in this prospective, observational case study. Patients were controlled at baseline and then monthly with microperimetry and assessment of distance visual acuity, reading ability, and SD- OCT. Side effects of the DEX implant were monitored by measuring the intraocular pressure (IOP) and lens grading with Lens Opacities Classification System (LOCS) charts.
RESULTS: The 23 patients with RVO included 16 patients with branch retinal vein occlusion (BRVO) and 7 patients with central retinal vein occlusion (CRVO). Improvement in distance visual acuity, reading ability, and in central 8-points microperimetry showed statistical significance from month 1 to 3, whereas the 40-points microperimetry improved with statistical significance from month 1 to 2. The reduction of central retinal thickness measured with SD-OCT remained statistically significant until month 4. Subgroup analysis of patients with BRVO and CRVO confirmed the best test results observed at month two after DEX implantation.
CONCLUSIONS: The highest macular sensitivity was measured two months after DEX implantation. This corresponds to the best test results for distance visual acuity, reading ability, and SD-OCT observed two months after treatment.

Entities:  

Keywords:  Macular disease; Microperimetry; Ozurdex; Retinal vein occlusion

Mesh:

Substances:

Year:  2015        PMID: 25576170     DOI: 10.1007/s00417-014-2897-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular edema with branch retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Katsunori Shimada
Journal:  Retina       Date:  2012-10       Impact factor: 4.256

2.  Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Umberto De Benedetto; Marialucia Cascavilla; Francesco Bandello
Journal:  J Ocul Pharmacol Ther       Date:  2012-07-02       Impact factor: 2.671

3.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

4.  Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion.

Authors:  Fevzi Senturk; Hakan Ozdemir; Murat Karacorlu; Serra Arf Karacorlu; Omer Uysal
Journal:  Retina       Date:  2010-09       Impact factor: 4.256

5.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

6.  Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.

Authors:  Lea Querques; Giuseppe Querques; Rosangela Lattanzio; Silvia Rita Gigante; Claudia Del Turco; Giulia Corradetti; Maria Lucia Cascavilla; Francesco Bandello
Journal:  Ophthalmologica       Date:  2012-09-19       Impact factor: 3.250

7.  Relationship between retinal microstructures on optical coherence tomography and microperimetry in age-related macular degeneration.

Authors:  Zhichao Wu; Lauren N Ayton; Chi D Luu; Robyn H Guymer
Journal:  Ophthalmology       Date:  2014-03-13       Impact factor: 12.079

8.  Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.

Authors:  Lukas Reznicek; Sarah Cserhati; Florian Seidensticker; Raffael Liegl; Anselm Kampik; Michael Ulbig; Aljoscha S Neubauer; Marcus Kernt
Journal:  Acta Ophthalmol       Date:  2013-05-07       Impact factor: 3.761

9.  Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function.

Authors:  Giuseppe Querques; Rosangela Lattanzio; Lea Querques; Giacinto Triolo; Maria L Cascavilla; Edoardo Cavallero; Claudia Del Turco; Giuseppe Casalino; Francesco Bandello
Journal:  Retina       Date:  2014-02       Impact factor: 4.256

10.  Foveal sensitivity and morphology in major and macular branch retinal vein occlusion.

Authors:  Hidetaka Noma; Katsunori Shimada; Tatsuya Mimura
Journal:  Open Ophthalmol J       Date:  2012-11-30
View more
  7 in total

1.  Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.

Authors:  Sibylle Winterhalter; Annabelle Eckert; Gerrit-Alexander Vom Brocke; Alice Schneider; Dominika Pohlmann; Daniel Pilger; Antonia M Joussen; Matus Rehak; Ulrike Grittner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-28       Impact factor: 3.117

2.  Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant.

Authors:  Sibylle Winterhalter; Gerrit Alexander Vom Brocke; Daniel Pilger; Annabelle Eckert; Juliane Schlomberg; Anne Rübsam; Matthias Karl Klamann; Enken Gundlach; Tina Dietrich-Ntoukas; Antonia Maria Joussen
Journal:  BMC Ophthalmol       Date:  2016-10-27       Impact factor: 2.209

Review 3.  New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion.

Authors:  Jia Li; Yannis M Paulus; Yuanlu Shuai; Wangyi Fang; Qinghuai Liu; Songtao Yuan
Journal:  J Ophthalmol       Date:  2017-03-12       Impact factor: 1.909

4.  Test-Retest Reproducibility of the Microperimeter MP3 With Fundus Image Tracking in Healthy Subjects and Patients With Macular Disease.

Authors:  Stefan Palkovits; Nino Hirnschall; Stefan Georgiev; Christoph Leisser; Oliver Findl
Journal:  Transl Vis Sci Technol       Date:  2018-02-07       Impact factor: 3.283

5.  Analysis of Morphologic and Functional Outcomes in Macular Edema due to Central Retinal Vein Occlusion Treated with Intravitreal Dexamethasone Implant.

Authors:  Alfredo Niro; Giancarlo Sborgia; Alessandra Sborgia; Luigi Sborgia; Claudio Furino; Nicola Recchimurzo; Giovanni Alessio
Journal:  J Ophthalmol       Date:  2018-09-09       Impact factor: 1.909

6.  Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion.

Authors:  Simone Donati; Carlo Gandolfi; Simona Maria Caprani; Jennifer Cattaneo; Laura Premoli; Claudio Azzolini
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

7.  Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series.

Authors:  Sibylle Winterhalter; Uwe Diedrich Behrens; Daniel Salchow; Antonia M Joussen; Uwe Pleyer
Journal:  BMC Ophthalmol       Date:  2017-12-16       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.